I completely agree and wouldn't rule out the US either. The first step was the DSMC. The next step is seeing what the regulatory agencies are willing to do with that report and supporting data. These are not instantaneous decisions and require some back and forth most likely. I have not given up hope of something coming from this interim analysis and believe patience is required.

As Dr. Kelly said previously, we are also building up a story of leronlimab each time we talk to these agencies. Next week's meeting with the MHRA, regardless of the fact that it is HIV specific is building the CytoDyn/Leronlimab story in the UK. Safety. Years of Data. Efficacy in more than one trial. I believe that will start to resonate at some point and the dam will burst. All IMO but frustrating that it is taking as long as it is and patients are suffering.